Shares of Proteostasis Therapeutics Inc (NASDAQ:PTI) have been given an average rating of “Buy” by the seven research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.88.
Several equities analysts recently issued reports on PTI shares. Cantor Fitzgerald reissued a “buy” rating and set a $14.00 price objective on shares of Proteostasis Therapeutics in a report on Monday, March 25th. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Friday, March 15th.
In other Proteostasis Therapeutics news, insider Meenu Chhabra sold 16,478 shares of Proteostasis Therapeutics stock in a transaction on Monday, February 4th. The shares were sold at an average price of $2.99, for a total value of $49,269.22. Following the transaction, the insider now directly owns 97,093 shares of the company’s stock, valued at $290,308.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 19.80% of the stock is currently owned by insiders.
Shares of PTI stock opened at $1.20 on Monday. The company has a market cap of $61.25 million, a P/E ratio of -0.75 and a beta of -0.95. Proteostasis Therapeutics has a 52-week low of $1.17 and a 52-week high of $10.38.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings data on Friday, March 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.10. Proteostasis Therapeutics had a negative net margin of 1,307.84% and a negative return on equity of 91.71%. As a group, equities analysts predict that Proteostasis Therapeutics will post -1.93 EPS for the current year.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.
Read More: Why do companies issue convertible shares?
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.